Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans [3]

Clinical Infectious Diseases

Volumn 34, Issue 8, 2002, Pages 1160-1161

  Rubin, Michael A ^a   Carroll, Karen C ^a   Cahill, Barbara C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CASPOFUNGIN; CORTICOSTEROID; ITRACONAZOLE;

ADULT; ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; FUNGUS CULTURE; HUMAN; IMMUNE DEFICIENCY; KIDNEY DYSFUNCTION; LETTER; LUNG LAVAGE; LUNG LOBECTOMY; MALE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 0037090279     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/339755     Document Type: Letter

References (1)

1. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant to amphotericin D (AMD), AMB lipid formulations (lipid AMB), or azoles